Hall Laurie J Trustee Sells 185 Shares of Danaher Corporation $DHR

Hall Laurie J Trustee cut its stake in shares of Danaher Corporation (NYSE:DHR) by 0.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 21,484 shares of the conglomerate’s stock after selling 185 shares during the quarter. Danaher makes up approximately 1.6% of Hall Laurie J Trustee’s holdings, making the stock its 22nd biggest position. Hall Laurie J Trustee’s holdings in Danaher were worth $4,404,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. Nuveen LLC bought a new stake in Danaher in the first quarter worth $833,941,000. GAMMA Investing LLC increased its stake in Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate’s stock worth $383,524,000 after purchasing an additional 1,863,381 shares during the period. Two Sigma Advisers LP increased its stake in shares of Danaher by 4,248.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate’s stock valued at $376,347,000 after buying an additional 1,601,800 shares during the period. Invesco Ltd. increased its stake in shares of Danaher by 44.5% during the first quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after buying an additional 1,450,703 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in shares of Danaher by 460.6% during the fourth quarter. Point72 Asset Management L.P. now owns 1,348,544 shares of the conglomerate’s stock valued at $309,558,000 after buying an additional 1,107,998 shares during the period. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Down 2.2%

Danaher stock opened at $199.40 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $279.90. The company has a market capitalization of $142.78 billion, a price-to-earnings ratio of 42.43, a price-to-earnings-growth ratio of 2.87 and a beta of 0.75. The stock has a 50-day moving average price of $201.94 and a 200 day moving average price of $199.49.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.Danaher’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the company posted $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Sell-side analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the company. Scotiabank raised Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective on the stock in a research report on Friday, July 11th. Royal Bank Of Canada set a $241.00 price objective on Danaher in a research report on Tuesday. Guggenheim reissued a “buy” rating and issued a $250.00 price target on shares of Danaher in a report on Wednesday, July 23rd. Wall Street Zen raised Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Finally, UBS Group lowered their price target on Danaher from $240.00 to $225.00 and set a “buy” rating for the company in a report on Wednesday, July 23rd. Seventeen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $246.35.

Insider Transactions at Danaher

In other Danaher news, Director Teri List sold 2,778 shares of the company’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This represents a 11.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 11.20% of the stock is currently owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.